ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Allergan boosts aesthetics business with Bonti buy

by Lisa M. Jarvis
September 21, 2018 | APPEARED IN VOLUME 96, ISSUE 38

 

Specialty pharmaceutical firm Allergan is boosting its aesthetics portfolio through the acquisition of privately held Bonti. In exchange for $195 million up front, Allergan gets a pipeline of fast-acting neurotoxins, including a novel botulinium neurotoxin serotype E in Phase II studies for both aesthetic and therapeutic applications. Allergan sells cosmetic and therapeutic versions of the neurotoxin Botox, which generated a combined $3.1 billion in sales last year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment